Rhodium complexes as therapeutic agents.

doi:10.1039/c5dt04338g

Paper

DOI: 10.1039/c5dt04338g

Rhodium complexes as therapeutic agents.

Published Feb 9, 2016 · Dik‐Lung Ma, Modi Wang, Zhifeng Mao

Dalton transactions

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

The landscape of inorganic medicinal chemistry has been dominated by the investigation of platinum, and to a lesser extent ruthenium, complexes over the past few decades. Recently, complexes based on other metal centers such as rhodium have attracted attention due to their tunable chemical and biological properties as well as distinct mechanisms of action. This perspective highlights recent examples of rhodium complexes that show diverse biological activities against various targets, including enzymes and protein-protein interactions.

Study Snapshot

Rhodium complexes show diverse biological activities against various targets, including enzymes and protein-protein interactions, offering potential therapeutic applications.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1039/c5cs00132c

Chemical biology of anticancer gold(III) and gold(I) complexes.

Gold complexes show potential as potent anticancer therapeutics, with some showing physiological stability and others showing potent in vitro and in vivo activity.

2015·315citations·Taotao Zou et al.·Chemical Society reviews

Chemical Society reviews

DOI: 10.1016/J.JORGANCHEM.2015.04.009

Synthesis, characterization and pharmacological evaluation of ferrocenyl azines and their rhodium(I) complexes

Ferrocenyl azines and their rhodium(I) complexes show weak to moderate activity against Plasmodium falciparum, with enhanced activity in resistant strains, and moderate cytotoxicity against WHCO1 oesophageal cancer cells.

2015·24citations·Tameryn Stringer et al.·Journal of Organometallic Chemistry

Journal of Organometallic Chemistry

DOI: 10.1021/ar500310z

Group 9 organometallic compounds for therapeutic and bioanalytical applications.

Group 9 organometallic compounds show potential as therapeutic agents and bioanalytical probes for targeting enzyme activity and protein-protein interactions in various diseases.

2014·209citations·Dik‐Lung Ma et al.·Accounts of chemical research

Accounts of chemical research

DOI: 10.1016/j.jinorgbio.2014.06.020

A rhodium(III) complex inhibits LPS-induced nitric oxide production and angiogenic activity in cellulo.

A novel rhodium(III) complex inhibits LPS-induced nitric oxide production and angiogenesis in human cells, potentially developing as effective anti-angiogenic agents.

2014·19citations·Li-Juan Liu et al.·Journal of inorganic biochemistry

Journal of inorganic biochemistry

DOI: 10.1002/anie.201404686

Antagonizing STAT3 dimerization with a rhodium(III) complex.

Rhodium complexes show potential as effective STAT3 inhibitors with potent anti-tumor activity in a mouse xenograft model of melanoma.

2014·119citations·Dik‐Lung Ma et al.·Angewandte Chemie

Angewandte Chemie

DOI: 10.1016/j.biochi.2014.03.005

Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme.

Piperacillin 1 shows high selectivity as an inhibitor of NEDD8-activating enzyme, potentially acting as a non-covalent ATP-competitive inhibitor.

2014·28citations·Hai‐Jing Zhong et al.·Biochimie

Biochimie

DOI: 10.1039/C3SC53243G

NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

NKP-1339 shows promising anticancer properties, with limited side effects in clinical trials, and shows potential synergistic activities with sorafenib for solid cancers.

2014·466citations·Robert Trondl et al.·Chemical Science

Chemical Science

DOI: 10.1016/j.cbpa.2014.01.005

Metal complexes as structural templates for targeting proteins.

Metal complexes show promise as structural templates for designing small-molecule protein binders, offering untapped chemical space for protein targeting.

2014·102citations·Markus Dörr et al.·Current opinion in chemical biology

Current opinion in chemical biology

DOI: 10.1002/CPLU.201400014

Antagonism of mTOR Activity by a Kinetically Inert Rhodium(III) Complex.

Rhodium(III) complex 1 is a potent mTOR inhibitor, showing potential as a protein-protein interaction modulator.

2014·29citations·Hai‐Jing Zhong et al.·ChemPlusChem

ChemPlusChem

Citations

DOI: 10.1016/j.poly.2024.117316

Assessment of four rhodium(I) complexes bearing SNS ligands for the catalytic reaction of chemical CO2 conversion to obtain cyclic carbonates

SNS-type Rh(I) complexes with DMAP show the highest catalytic activity and selectivity for CO2 conversion to cyclic carbonates, with L3-Rh showing the highest selectivity under optimal conditions.

2024·0citations·H. G. Sogukomerogullari et al.·Polyhedron

Polyhedron

DOI: 10.1016/j.ica.2022.120936

Crystal Structure, Optical Properties, Spectroscopic Characterization and Density Functional Theory Studies of a New Rhodium(I)-Imidazolidin-2-ylidene Complexes: Synthesis, Characterization and Cytotoxic Properties

Rhodium(I)-Imidazolidin-2-ylidene complexes show 100% anticarcinogenic effect in various human cancer cell lines at 50 and 100 M concentrations.

2022·4citations·Emine Özge Karaca et al.·Inorganica Chimica Acta

Inorganica Chimica Acta

DOI: 10.1016/j.molstruc.2022.132584

Quercetin - Based Rhodium(III) Complex: Synthesis, Characterization and Diverse Biological Potentials

The quercetin-based rhodium(III) complex shows promising anti-proliferative properties and minimal toxicity to normal cells, making it a promising cancer treatment option.

2022·8citations·H. Sahyon et al.·Journal of Molecular Structure

Journal of Molecular Structure

DOI: 10.1016/j.jorganchem.2022.122300

Microwave assisted synthesis of rhodium(+Ⅰ) N-heterocyclic carbene complexes and their cytotoxicity against tumor cell lines

Microwave assisted synthesis of rhodium(I) N-heterocyclic carbene complexes led to strong cytotoxic effects against cancer cell lines, with a preference for branched isopropyl side chains.

2022·4citations·J. Schmidt et al.·Journal of Organometallic Chemistry

Journal of Organometallic Chemistry

DOI: 10.1039/D1NJ00144B

Rhodium(i) N-heterocyclic carbene complexes: synthesis and cytotoxic properties

Rhodium(I) N-heterocyclic carbene complexes show strong cytotoxic activity against various cancer cells, with complex 2b showing the most selective activity against HT-29 and Ishikawa cancer cells.

2021·5citations·I. Slimani et al.·New Journal of Chemistry

New Journal of Chemistry

DOI: 10.1016/j.jinorgbio.2021.111400

Mitochondrial targeted rhodium(III) complexes: Synthesis, characterized and antitumor mechanism investigation.

Rhodium complexes Rh1 and Rh2 show stronger anticancer activity than cisplatin and effectively target mitochondrial metabolism, offering a strategy for creating highly effective anticancer agents.

2021·12citations·Yan-Bo Peng et al.·Journal of inorganic biochemistry

Journal of inorganic biochemistry

DOI: 10.1016/j.ejmech.2021.113308

Recent advances in biological activities of rhodium complexes: Their applications in drug discovery research.

Rhodium complexes show potential as versatile anti-cancer drugs due to their unique structure, reactivity, and facile synthesis, making them promising candidates for drug discovery.

2021·38citations·M. Sohrabi et al.·European journal of medicinal chemistry

European journal of medicinal chemistry

DOI: 10.1039/d1dt00216c

A novel ruthenium polypyridyl complex for the selective imaging and photodynamic targeting of the Golgi apparatus.

The Ru-SL complex effectively selectively images and targets the Golgi apparatus in cells, enabling photodynamic therapy and estimating cell viability based on fluorescence signal intensity.

2021·3citations·Fengyi Zhao et al.·Dalton transactions

Dalton transactions